



Biocon Limited

20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

November 16, 2022

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol – Biocon
--	---

Subject: Newspaper Advertisement- Unaudited Financial Results for Quarter and Half-year ended September 30, 2022

Dear Sir/Madam,

In continuation to our letter dated November 14, 2022 with regard to the Unaudited Financial Results for the quarter and half-year ended September 30, 2022, please find enclosed copies of newspaper advertisement published in Financial Express (English Language-All India Edition) and Vijayavani (Kannada-Bengaluru Edition) on November 16, 2022.

The above information is also available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank Verma
Company Secretary & Compliance Officer
Membership No.: ACS 18776

Enclosed: Copies of Newspaper advertisements

SHANTI OVERSEAS (INDIA) LIMITED
CIN: L51211MP2011PLC025807
Regd. Office : 203, 2nd Floor, N.M. Verge, 8/5 Yeshwant Niwas Road, Indore (M.P.) - 452003
Website: www.shantioverseas.com ; E-mail: mail@shantioverseas.com ; Tel: +91-731-4020586, +91-731-4020587
Extract of Consolidated Unaudited Financial Results for the Quarter and Half Year ended on 30th September, 2022
(₹ in Lakhs)

Sr. No.	Particulars	Quarter ended			Half Year Ended			Year Ended
		30/09/2022	30/06/2022	30/09/2021	30/09/2022	30/09/2021	31/03/2022	(Audited)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
1	Total Income From Operation	3,711.29	9,912.84	741.46	13,624.14	3,468.26	20,307.18	
2	Net Profit / (Loss) (before taxes and Extraordinary items)	(281.80)	(221.59)	(341.10)	(503.39)	(349.26)	334.93	
3	Net Profit / (Loss) before taxes (after Extraordinary items)	(281.80)	(221.59)	(341.10)	(503.39)	(349.26)	334.93	
4	Net Profit / (Loss) after taxes (after Extraordinary items)	(278.97)	(218.04)	(294.55)	(497.02)	(302.71)	309.70	
5	Total Comprehensive Income for the period (comprising profit (loss) and other comprehensive income for the period after tax)	(278.84)	(217.29)	(294.55)	(496.14)	(302.71)	312.70	
6	Paid-up equity share capital (Face Value Rs.10/- each)	1,110.60	1,110.60	1,110.60	1,110.60	1,110.60	1,110.60	
7	Reserve (excluding Revaluation Reserves as per balance sheet of previous accounting year)	-	-	-	-	-	2,128.32	
8	Earnings per share (for discontinued & continuing operation) :							
	(a) Basic	(2.51)	(1.96)	(2.65)	(4.48)	(2.73)	2.79	
	(b) Diluted	(2.51)	(1.96)	(2.65)	(4.48)	(2.73)	2.79	

1 The Consolidated financial results for the quarter and half year ended 30th September, 2022 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning 1st April, 2020, the Company has for the first time adopted Ind AS with the transition date of 1st April, 2019.

2 Additional information on standalone financial results are given below:
(₹ in Lakhs)

Sr. No.	Particulars	Quarter ended			Half Year Ended			Year Ended
		30/09/2022	30/06/2022	30/09/2021	30/09/2022	30/09/2021	31/03/2022	(Audited)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
i	Total Income from operations (net)	283.71	1,637.33	603.50	1,921.04	3,312.05	7,014.40	
ii	Profit/Loss before tax	(153.10)	(121.03)	(274.87)	(274.13)	(168.35)	57.79	
	Profit/Loss after tax	(151.27)	(118.67)	(252.94)	(269.94)	(124.49)	50.65	

3 The above results were reviewed by the audit committee at their meeting held on 14th November, 2022 and thereafter approved by Board of Directors at their meeting held on 14th November, 2022.

4 The previous period figures have been regrouped/rearranged wherever found necessary.

5 The above is an extract of the detailed format of Consolidated and Standalone Financial Results for the quarter ended on 30th September, 2022 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Consolidated and Standalone Financial Results for the quarter ended on 30th September, 2022 are available on the website of the company i.e. www.shantioverseas.com and on the website of NSE (www.nseindia.com).

Place: Indore
Date: 14/11/2022

Ayush Kacholia
Managing Director
DIN : 03096933

GENESIS FINANCE COMPANY LIMITED
CIN: L65910DL1990PLC040705
Regd. Off: 4 MMTCT/STC MARKET, GEETANJALI, NEW DELHI-110017
E-mail: gbsist@genesisfinance.net | Website: www.genesisfinance.net
Phone: 011-42181244
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2022
(Amount in INR Lakhs)

S. No.	Particulars	Quarter ended on		
		September 30, 2022	September 30, 2021	September 30, 2022
		Unaudited	Unaudited	Unaudited
1	Total Income From Operations	742.00	600.52	1446.63
2	Net Profit/(Loss) for the quarter/half-year (before tax, exceptional and/Extraordinary items)	482.47	326.81	862.83
3	Net Profit / (Loss) for the quarter/ half-year before tax (after Exceptional and/or Extraordinary items)	482.47	326.81	862.83
4	Net Profit / (Loss) for the quarter/ half-year after tax (after Exceptional and/or Extraordinary items)	364.19	244.54	642.15
5	Total Comprehensive Income for the quarter/ half-year [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	364.19	244.54	642.15
6	Equity Share Capital	4639.71	4639.71	4639.71
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	0.00	0.00	0.00
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)-			
	1. Basic	0.78	0.53	1.38
	2. Diluted	0.78	0.53	1.38

Notes:

- The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial results is available on the Company's website www.genesisfinance.net and Stock Exchange's website www.nseindia.com.
- The Company has adopted Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 (the "Act") read with Companies (Indian Accounting Standard) Rules, 2015 as amended till date, from April 01, 2019.

Place: New Delhi
Date: 15.11.2022

For Genesis Finance Company Limited
Sd/-
Gopal Bisht
(Whole Time Director and CFO)
DIN: 00597160

B.C. POWER CONTROLS LIMITED
CIN: L31300DL2008PLC179414
Regd. Office: 7A/39, WEA Channa Market, Karol Bagh, New Delhi-110005
Website: www.bcpowercontrols.com; E-mail: info@bonlongroup.com; Tel: 011-47532792-95; Fax: 011-47532798
Extract of Standalone Un-Audited Financial Results for the Quarter Ended September 30, 2022
(₹ in Lakhs except per share data)

Sl. No.	Particulars	Quarter ended	Previous Year	Corresponding
		30.09.2022	Ended 31.03.2022	Quarter ended
		(Un-Audited)	(Audited)	of the previous year
		30.09.2021	30.09.2021	30.09.2021
		(Un-Audited)	(Audited)	(Un-Audited)
1	Total Income from Operations	274.58	10,640.61	4,263.02
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	39.49	179.90	(3.58)
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	39.49	179.90	(3.58)
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	29.51	157.06	(2.79)
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	29.51	157.06	(2.79)
6	Equity Share Capital	1,176.00	1,176.00	1,176.00
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	2126.93
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations)-			
	(a) Basic (in ₹)	0.050	0.270	(0.005)
	(b) Diluted (in ₹)	0.050	0.270	(0.005)

Notes:

- The above is an extract of the detailed format of un-audited Standalone Financial Results for the quarter ended September 30, 2022 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone Financial Results for the quarter ended September 30, 2022 are available on the Stock Exchange website www.bseindia.com and on the Company's website www.bcpowercontrols.com.

For and on behalf of the Board of Directors
For B.C. POWER CONTROLS LIMITED
Sd/-
CHANDER SHEKHAR JAIN
MANAGING DIRECTOR
DIN-08639491

Place : New Delhi
Date : 14.11.2022

EDELWEISS MUTUAL FUND
Edelweiss House, Off C.S.T Road, Kalina, Mumbai – 400098

NOTICE
RECORD DATE FOR DISTRIBUTION UNDER INCOME DISTRIBUTION CUM CAPITAL WITHDRAWAL OPTION (IDCW OPTION)

NOTICE is hereby given that Edelweiss Trustee Company Limited, Trustee to Edelweiss Mutual Fund, has approved declaration of IDCW Options under the following Schemes of Edelweiss Mutual Fund, as per the details given below:

Name of the Scheme/Plan/Option	Amount of IDCW	Record Date	NAV per unit as on November 14, 2022	Face Value per unit
Edelweiss Balanced Advantage Fund - Direct Plan Monthly IDCW Option	₹ 0.15 per unit*	Monday, November 21, 2022**	₹ 23.26	₹ 10.00
Edelweiss Balanced Advantage Fund - Regular Plan Monthly IDCW Option	₹ 0.15 per unit*		₹ 20.28	
Edelweiss Equity Savings Fund - Direct Plan Monthly IDCW Option	₹ 0.08 per unit*		₹ 14.0903	
Edelweiss Equity Savings Fund - Regular Plan Monthly IDCW Option	₹ 0.08 per unit*		₹ 13.039	
Edelweiss Aggressive Hybrid Fund - Direct Plan IDCW Option	₹ 0.15 per unit*		₹ 25.19	
Edelweiss Aggressive Hybrid Fund - Regular Plan IDCW Option	₹ 0.15 per unit*		₹ 22.22	

Pursuant to payment of IDCW, the NAV of the aforementioned IDCW Options of the Schemes will fall to the extent of payout and statutory levy, if any.

*Distribution of the above IDCW is subject to availability of distributable surplus as on the Record Date and as reduced by the amount of applicable statutory levy, if any. Considering the volatile nature of the markets, the Trustee reserves the right to restrict the quantum of IDCW upto the per unit distributable surplus available under the Schemes on the Record Date in case of fall in the market.

**or the immediately following Business Day if that day is a Non-Business Day.

All Unit holders whose name appears in the Register of Unit holders of the aforementioned IDCW Options of the Schemes as at the close of business hours on the Record Date shall be eligible to receive the IDCW so declared.

Investors are requested to take note of the above.

For Edelweiss Asset Management Limited
(Investment Manager to Edelweiss Mutual Fund)
Sd/-
Radhika Gupta
Managing Director & CEO
(DIN: 02657595)

Place : Mumbai
Date : November 15, 2022

For more information please contact:
Edelweiss Asset Management Limited (Investment Manager to Edelweiss Mutual Fund)
CIN: U65991MH2007PLC173409
Registered Office & Corporate Office: Edelweiss House, Off C.S.T Road, Kalina, Mumbai – 400 098.
Tel No: +91 22 4097 9737, Toll Free No. 1800 425 0090 (MTNL/BSNL), Non Toll Free No. 91 40 23001181, Fax: +91 22 40979878,
Website: www.edelweissmf.com

**MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS,
READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.**

CHITRALI PROPERTIES PRIVATE LIMITED
Registered Office : 93/ 5A, Erandwane, Pune 411 004.
CIN : U70109MH1995PTC094686
Extract of Standalone Unaudited Financial Results for the quarter and half year ended 30 September 2022
(Rs. in millions unless otherwise stated)

Sr.No.	Particulars	Quarter Ended	Half Year Ended	Half Year Ended	Previous Year Ended
		September 30, 2022	September 30, 2022	September 30, 2021	March 31, 2022
		Unaudited	Unaudited	Unaudited	Audited
1	Total Income From Operations	242.55	480.72	153.51	481.91
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	36.71	80.94	(171.05)	(201.75)
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	36.71	80.94	(171.05)	(201.75)
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	14.58	36.90	(149.04)	(197.37)
5	Total Comprehensive Income for the period Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)	22.63	36.90	(148.51)	(196.11)
6	Paid up Equity Share Capital	20.00	20.00	20.00	20.00
7	Reserves (excluding Revaluation Reserve)	(761.71)	(761.71)	(752.72)	(798.62)
8	Securities Premium Account	810.66	810.66	810.66	810.66
9	Net Worth	68.95	68.95	77.94	32.04
10	Paid up Debt Capital / Outstanding Debt	4,417.60	4,417.60	4336.34	4,422.34
11	Outstanding Redeemable Preference Shares	710.85	710.85	633.83	669.61
11	Debt Equity Ratio	64.07	64.07	55.64	138.01
	Earning per share (of Rs.10/- each) (for continuing and discontinued operations)				
	1. Basic	7.30	18.45	(74.52)	(98.06)
	2. Diluted	7.30	18.45	(74.52)	(98.06)
13	Capital Redemption Reserve	-	-	-	-
14	Debenture Redemption Reserve	-	-	-	-
15	Debt Service Coverage Ratio	1.99	2.06	0.41	0.94
16	Interest Service Coverage Ratio	2.37	2.49	0.11	0.79
17	Current Ratio	1.13	1.13	0.30	0.52
18	Long Term debt to Working capital ratio	25.69	25.69	(44.67)	(133.01)
19	Baddebts to Accounts receivable ratio	0.65%	0.65%	-	-0.12%
20	Current liability ratio	0.09	0.09	0.10	0.11
21	Total debts to total assets ratio	0.90	0.90	0.90	0.90
22	Debtors turnover ratio	6.50	13.17	2.02	8.20
23	Inventory turnover ratio	NA	NA	NA	NA
24	Operating margin %	56.83%	0.57	0.09	32.25%
25	Net profit margin %	6.02%	6.02%	-111.43%	-40.96%

Notes:-

- The above is an extract of the detailed format of annual financial results filed with Bombay Stock Exchange under Regulation 52 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly and annual financial results are available on the website of Bombay Stock Exchange i.e. www.bseindia.com.
- For the other line items referred in regulation 52 (4) of the Listing Regulations, pertinent disclosures have been made to the Bombay Stock Exchange and can be accessed on the URL www.bseindia.com.
- The impact on net profit / loss, total comprehensive income or any other relevant financial item(s) due to change(s) in accounting policies shall be disclosed by means of a footnote.

Place : Pune
Date : 14/11/2022

For and on behalf of the Board of Directors of
Chitrali Properties Private Limited
Sd/-
Virendrasingh Thakur
Director
DIN: 0009562470

KWALITY PHARMACEUTICALS LTD.
Regd. Office: VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR - 143601
CIN: L24232PB1983PLC005426; Ph.: 8558820862
Email Id: cs@kwalitypharma.com; Website: www.kwalitypharma.com
EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2022
(Rupees in Lacs except EPS)

Sr. No.	Particulars	Quarter Ended	Half year Ended	Quarter Ended
		30.09.2022	30.09.2022	30.09.2021
		Unaudited	Unaudited	Unaudited
1.	Total Income from Operations	5580.53	12602.39	18373.80
2.	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	1166.06	2530.52	8014.16
3.	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	1166.06	2530.52	8014.16
4.	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	939.24	1953.70	5961.91
5.	Total Comprehensive Income for the period (Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax))	915.48	1926.29	5948.30
6.	Equity Share Capital	1037.62	1037.62	1037.62
7.	Reserves (excluding Revaluation Reserve as shown in the Audited Balance Sheet of the previous year)	-	-	-
8.	Earning Per Share (of Rs. 10/- each)			
	1. Basic:	8.82	18.56	57.33
	2. Diluted:	8.82	18.56	57.33

Notes:

- Key Standalone Financial Information (Rupees in Lacs)

Sr. No.	Particulars	Quarter Ended	Half year Ended	Quarter Ended
		30.09.2022	30.09.2022	30.09.2021
		Unaudited	Unaudited	Unaudited
1.	Total Income from Operations	5596.29	12618.14	18371.24
2.	Net Profit for the period before tax	1131.60	2536.56	8018.01
3.	Net Profit for the period after tax	904.78	1959.74	5965.76

2 The above results were reviewed by the Audit Committee on 14th November, 2022 and approved by the Board of Directors of the Company at its meeting held on 14th November, 2022.

3 The above is an extract of the detailed format of Quarterly and Half Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the website of the Stock Exchange(s) and on the Company's website (www.kwalitypharma.com)

FOR AND ON BEHALF OF THE BOARD
For KWALITY PHARMACEUTICALS LIMITED
Sd/-
Ramesh Arora
Managing Director
DIN: 00462656

Place: Amritsar
Date : 14.11.2022

Biocon
Registered Office: Biocon Limited, 20th KM Hosur Road, Electronic City PD, Bangalore - 560 100
www.biocon.com
CIN: L24236KA1978PLC003417
EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2022
(Rs. in Million, except per equity share data)

Particulars	3 months ended		
	30.09.2022	6 months ended 30.09.2022	3 months ended 30.09.2021
	Unaudited	Unaudited	Unaudited
I Total income from operations	23,197	44,592	18,404
II Net profit before tax, exceptional items and non-controlling interest	2,461	4,430	2,761
III Net profit before tax and non-controlling interest	2,291	4,260	2,060
IV Profit after tax and non-controlling interest	469	1,913	1,383
V Total comprehensive income for the period attributable to shareholders [comprising profit for the period (after tax) and other comprehensive income (after tax)]	797	1,871	2,068
VI Paid-up equity share capital [Face value of Rs. 5 each]	6,003	6,003	6,003
VII Earnings per share [of Rs. 5 each]			
(a) Basic	0.39	1.60	1.16
(b) Diluted	0.39	1.60	1.16

1. Key standalone financial information

Particulars	3 months ended		
	30.09.2022	6 months ended 30.09.2022	3 months ended 30.09.2021
	Unaudited	Unaudited	Unaudited
I Total income from operations	4,895	9,312	3,648
II Profit/(loss) before tax	11,061	11,286	(93)
III Profit/(loss) after tax	9,875	10,024	(66)

2. The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2022 in respect of Biocon Limited ("the Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on November 14, 2022. The reports of the statutory auditors are unqualified.

3. These financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


4. The above is an extract of the detailed format of unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.biocon.com.

PATNA ELECTRIC SUPPLY CO LTD
CIN: L40109WB1956PLC023307
Regd. Office: 3 Khetra Das Lane, 1st Floor, Kolkata-700012 (West Bengal)
Email: pesclco@gmail.com; Website: www.patnaelectricssupplyco.com
Extract of Statement of Unaudited Financial Results for the Quarter and half-year ended September 30, 2022
(₹ in lakhs)

S. No.	Particulars	Quarter ended	Half year ended	Quarter ended
		30.09.2022	30.0	

Registered Office:
Biocon Limited
20th KM Hosur Road,
Electronic City P.O.,
Bangalore - 560 100

www.biocon.com
CIN: L24234KA1978PLC003417



EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2022

(Rs. in Million, except per equity share data)

Particulars	3 months ended 30.09.2022	6 months ended 30.09.2022	3 months ended 30.09.2021
	Unaudited	Unaudited	Unaudited
I Total income from operations	23,197	44,592	18,404
II Net profit before tax, exceptional items and non-controlling interest	2,461	4,430	2,761
III Net profit before tax and non-controlling interest	2,291	4,260	2,060
IV Profit after tax and non-controlling interest	469	1,913	1,383
V Total comprehensive income for the period attributable to shareholders [comprising profit for the period (after tax) and other comprehensive income (after tax)]	797	1,871	2,068
VI Paid-up equity share capital [Face value of Rs. 5 each]	6,003	6,003	6,003
VII Earnings per share [of Rs. 5 each]	(not annualised)	(not annualised)	(not annualised)
(a) Basic	0.39	1.60	1.16
(b) Diluted	0.39	1.60	1.16

1. Key standalone financial information

Particulars	3 months ended 30.09.2022	6 months ended 30.09.2022	3 months ended 30.09.2021
	Unaudited	Unaudited	Unaudited
I Total income from operations	4,895	9,312	3,648
II Profit/(loss) before tax	11,061	11,286	(93)
III Profit/(loss) after tax	9,875	10,024	(66)

- The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2022 in respect of Biocon Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on November 14, 2022. The reports of the statutory auditors are unqualified.
- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above is an extract of the detailed format of unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.biocon.com.